The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,